Related Experiment Videos
[Further study on gentamicin in pediatrics (author's transl)]
Insights
Gentamicin (GM) effectively treated pediatric infectious diseases in 16 children, showing a 100% efficacy rate. Doses were adjusted safely, demonstrating GM
Area of Science:
- Pediatric Infectious Diseases
- Antibiotic Chemotherapy
- Pharmacology
Context:
- Gentamicin (GM) is an aminoglycoside antibiotic.
- Pediatric infections require effective and safe treatment options.
- Assessing antibiotic efficacy and safety in pediatric populations is crucial.
Purpose:
- To evaluate the clinical efficacy and safety of intramuscular gentamicin in pediatric patients with various infectious diseases.
- To determine optimal gentamicin dosage regimens for different pediatric infections.
- To identify gentamicin's potential role as a first-line antibiotic in specific pediatric bacterial infections.
Summary:
- Intramuscular gentamicin demonstrated 100% clinical effectiveness in 16 pediatric patients across diverse infections, including septicemia, meningitis, and pneumonia.
- Dosage adjustments, including increases to 5-8 mg/kg/day, yielded satisfactory results without observed renal, hepatic, or ototoxic adverse effects within 18 days.
- Gentamicin is recommended for infections caused by Staphylococcus and gram-negative bacilli, particularly in penicillin/cephalosporin-hypersensitive children, though further safety studies on dosage and duration are warranted.
Impact:
- Establishes gentamicin as a highly effective first-line treatment for various pediatric bacterial infections.
- Provides evidence for safe and effective gentamicin dosing strategies in children.
- Supports the use of gentamicin in pediatric patients with hypersensitivity to other antibiotic classes.
Abstract:
Gentamicin (GM) was intramuscularly injected to 16 children with various infectious disease (1 septicemia, 1 purulent meningitis, 4 bronchopneumonia, 1 pyothorax, 3 pyelonephritis, 2 acute cystitis and 4 RITTER'S dermatitis). The results obtained are as follows: 1. The excellent and good clinical results were noted in all patients except for an indeterminate case with bronchopneumonia because of the concomitant therapy with CEZ. The effective rate was 100.0%. This was possibly because of quite high susceptibility (See Article) of all isolates to gentamicin. 2. Doses of GM were adjusted depending on the style of infectious diseases. The satisfactory clinical results were obtained in some cases by increasing its recommended dosage to about 5-8 mg per kg per day. 3. No kidney dysfunction, liver dysfunction, the 8th cranial nerve damage, etc. were observed by administering 5 to 8 mg per kg per day for at maximum 18 days, in this clinical trial. 4. It has been indicated in this clinical trial that GM is worthy to be used as a first-choice drug in chemotherapy of infectious diseases caused by Staphylococcus, gram-negative bacillus, etc., especially in patients who are hypersensitive to penicillin and cephalosporin derivatives. However, further study would be required for the safety of increase in its dosage and duration of administration.